Sunday, August 1, 2021

FDA Approves Verkazia (cyclosporine ophthalmic emulsion) for the Treatment of Vernal Keratoconjunctivitis

- Advertisement -
- Advertisement -

Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on eye care, today announced that the U.S. Food and Drug Administration (FDA) has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.

- Advertisement -

Latest news

- Advertisement -

Related news

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here